Alerts will be sent to your verified email
Verify Email
FDC
|
FDC
|
Viyash Scientific
|
Zota Health Care
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
5.1 % | n/a | n/a |
|
R&D as a % of Total Sales
|
2.22 % | 0.0 | 0.09 % |
|
Financials
|
|||
|
5 yr Average ROE
|
12.9 % | -0.13 % | -7.74 % |
|
5yr average Equity Multiplier
|
1.57 | 2.16 | 1.84 |
|
5yr Average Asset Turnover Ratio
|
0.55 | 0.95 | 0.91 |
|
5yr Avg Net Profit Margin
|
15.2 % | 0.03 % | -4.95 % |
|
Price to Book
|
2.47 | 6.51 | 14.1 |
|
P/E
|
26.65 | 126.07 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
-13.89 Days | 49.09 Days | 40.5 Days |
|
Inventory Days
|
61.89 Days | 80.25 Days | 91.82 Days |
|
Days Receivable
|
18.98 Days | 79.76 Days | 42.2 Days |
|
Days Payable
|
89.17 Days | 114.46 Days | 92.36 Days |
|
5yr Average Interest Coverage Ratio
|
90.41 | 1.93 | 5.98 |
|
5yr Avg ROCE
|
13.8 % | 6.67 % | -2.72 % |
|
5yr Avg Operating Profit Margin
|
17.7 % | 7.74 % | 3.69 % |
|
5 yr average Debt to Equity
|
0.0 | 0.53 | 0.04 |
|
5yr CAGR Net Profit
|
-2.41 % | -25.52 % | 206.06 % |
|
5yr Average Return on Assets
|
8.22 % | 0.05 % | -3.4 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
69.66 % | 61.41 % | 55.81 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.26 % |
|
Change in Promoter Holding (3 Yrs)
|
0.17 % | 8.62 % | -12.31 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-1.33 % | 5.57 % | 0.06 % |
|
FDC
|
Viyash Scientific
|
Zota Health Care
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|